Navigation Links
YMed, Inc. Successfully Completes First Clinical Cases With Innovative VascuTraK(TM) II PTA Dilatation Catheter
Date:12/10/2007

SAN DIEGO, Dec. 10 /PRNewswire/ -- YMed, Inc. announced today that it has successfully completed its first U.S. cases with its proprietary VascuTraK(TM) II PTA Dilatation Catheter. The VascuTraK(TM) II PTA Catheter is a unique 5F compatible, single operator rapid exchange system.

YMed's VascuTraK(TM) II catheter is designed and indicated for vascular intervention of a wide range of peripheral arteries including the treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistulae.

"The VascuTraK(TM) II catheter is an important advancement in technology for the treatment of patients with peripheral vascular disease (PVD), especially below the knee where amputation risks are the greatest," says Dr. Rajesh Dave, Chairman, Endovascular Medicine, Harrisburg Hospital, Harrisburg, PA. Dr. Dave performed the initial clinical cases with commercially available VascuTraK(TM) II catheters. He noted that in some lesion subsets, including calcified lesions involving the popliteal artery, the VascuTraK(TM) II catheter was sufficient to complete the intervention without adjunctive devices that may increase restenois or require further intervention.

YMed plans to initiate U.S. Sales with a broad range of VascuTraK(TM) II PTA dilatation catheters during Q1 2008, says Richard Cooper, Vice President Sales & Marketing, YMed, Inc. "The VascuTraK(TM) II is the first PTA dilatation catheter to combine the features of plaque modification and longer balloon lengths," Mr. Cooper added. Balloon diameters range from 2.0 mm to 4.0 mm in 0.5 mm increments with balloon lengths of 20 mm to 120 mm.

YMed, Inc. is a privately held Corporation established in 2004. The company was founded and is managed by a highly experienced, multinational team of medical, engineering and business professionals from within the cardio and peripheral vascular industry. This team develops, manufactures and markets innovative products for vascular intervention provi
'/>"/>

SOURCE YMed, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
3. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
6. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
7. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
8. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
9. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
10. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
11. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... is available in its catalogue: ... Drug Forecast and Market Analysis to 2022 ... PharmaPoint: Atopic Dermatitis - India Drug Forecast ...
(Date:1/15/2014)... wearable injector slightly larger than an Oreo cookie may soon ... drugs in the large doses required to treat a wide ... genetic disorders.  An emerging biologic drugs market ... analysts.   Many of these drugs will require a new type ...
(Date:1/14/2014)... Pa. , Jan. 14, 2014 Dynamic Healthcare Services, ... announced today that it acquired Progressive Home Medical Equipment, Inc. ... 7, 2014. The terms of the acquisition were not disclosed. ... equipment ("DME") company providing a wide range of sleep, mobility, ...
Breaking Medicine Technology:PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3
... 8, 2011 Regeneron Pharmaceuticals, Inc. (NASDAQ: ... that they have initiated the first of two Phase ... VEGF Trap-Eye (aflibercept ophthalmic solution), an investigational new agent ... treatment of Diabetic Macular Edema (DME).  The companies are ...
... (NASDAQ: IDIX ), a biopharmaceutical company engaged in ... human viral diseases, today announced that it has commenced an ... All of these shares are being sold by Idenix. ... book-running manager and underwriter for the offering. Idenix intends to ...
Cached Medicine Technology:Regeneron and Bayer Announce Start of Phase 3 Clinical Program in Diabetic Macular Edema 2Regeneron and Bayer Announce Start of Phase 3 Clinical Program in Diabetic Macular Edema 3Regeneron and Bayer Announce Start of Phase 3 Clinical Program in Diabetic Macular Edema 4Regeneron and Bayer Announce Start of Phase 3 Clinical Program in Diabetic Macular Edema 5Regeneron and Bayer Announce Start of Phase 3 Clinical Program in Diabetic Macular Edema 6Idenix Pharmaceuticals Announces Proposed Public Offering of Common Stock 2
(Date:4/18/2014)... (April 21, 2014) -- A group of scientists ... and the Sanders-Brown Center on Aging has found ... and neuropsychological function in Parkinson,s disease (PD). ... , the study, which assessed cognitive function in ... the dopamine replacement therapy commonly used to treat ...
(Date:4/18/2014)... The Gerontologist reports that among older Christians, ... in anxiety about death and increases in life satisfaction, ... particular, listening to gospel music is associated with a ... sense of control. , These associations are similar for ... both low- and high-socioeconomic status. , The article, titled ...
(Date:4/18/2014)... have been awarded two-year grants for their work on ... Of the 110 initial submissions to the new Novo ... four projects were funded, three of which are led ... Ph.D.; G. William Wong, Ph.D.; and Elias Zambidis, M.D., ... will use his $500,000 proof of principle grant to ...
(Date:4/18/2014)... April 18, 2014) Benaroya Research Institute at Virginia ... blocking a particular molecule in metastatic breast cancer reduces ... of lung metastases. BRI scientists have found in models ... tumors by 60 - 80 percent and can keep ... The $1.8 million five-year grant comes from the National ...
(Date:4/18/2014)... new study in the American Journal of Preventive ... reveals a recurring pattern that could be leveraged to ... San Diego State University, the Santa Fe Institute, Johns ... searches (searches that included the term healthy and were ... from 2005 to 2012. They found that on average, ...
Breaking Medicine News(10 mins):Health News:Treating depression in PD patients: New research 2Health News:Religious music brings benefit to seniors' mental health 2Health News:Benaroya Research Institute evaluates immunology approach to blocking breast cancer 2Health News:New research shows people are thinking about their health early in the week 2
... Hopkins and elsewhere report what is believed to be ... inflammation of heart tissue and the subsequent damage leading ... latest findings from the Multiethnic Study of Atherosclerosis (MESA), ... the Journal of the American College of Cardiology, appear ...
... at Mattel Children,s Hospital UCLA have found that low-dose antidepressant ... adolescents suffering from irritable bowel syndrome, or IBS. ... students and 14 percent of high school kids in the ... the May issue of the peer-reviewed Journal of Pediatrics, is ...
... WASHINGTON, May 1 Speaker Nancy Pelosi today,released ... Information,Nondiscrimination Act, which the House passed this afternoon ... bill, which would prohibit health,insurance companies and employers ... test results, now goes to the President,s desk ...
... said today that there are more than 36,000 uninsured ... whom are on a waiting,list to receive health care ... a plan to help them gain access to health ... live with the,very real fear that a sudden illness ...
... Courage Center has received a,one-year grant of $150,000 ... to,support The Bridge to Independence. This coordinated campaign ... children with disabilities,through effective grassroots community organizing, policy ... leading member of the Minnesota Consortium of Citizens ...
... Shire plc (LSE: SHP, NASDAQ: SHPGY), the global ... present key scientific data on its Attention Deficit ... system and the investigational non-stimulant treatment under FDA ... Association (APA) annual meeting to be held May ...
Cached Medicine News:Health News:Study in 7,000 men and women ties obesity, inflammatory proteins to heart failure risk 2Health News:Study in 7,000 men and women ties obesity, inflammatory proteins to heart failure risk 3Health News:Antidepressant found to alleviate symptoms of irritable bowel syndrome in adolescents 2Health News:Pelosi: 'Genetic Information Nondiscrimination Act Will Protect Americans from Misuse of Genetic Information' 2Health News:Governor Rendell Says Passage of PA ABC Would Help More Than 36,000 Uninsured Citizens Living in the Lehigh Valley 2Health News:Governor Rendell Says Passage of PA ABC Would Help More Than 36,000 Uninsured Citizens Living in the Lehigh Valley 3Health News:Governor Rendell Says Passage of PA ABC Would Help More Than 36,000 Uninsured Citizens Living in the Lehigh Valley 4Health News:Governor Rendell Says Passage of PA ABC Would Help More Than 36,000 Uninsured Citizens Living in the Lehigh Valley 5Health News:Governor Rendell Says Passage of PA ABC Would Help More Than 36,000 Uninsured Citizens Living in the Lehigh Valley 6Health News:Courage Center Receives $150,000 Grant From Minneapolis Foundation 2Health News:Shire to present ADHD treatments scientific data at American Psychiatric Assoc. Meeting 2
Drug controls sera available in three levels for the control of accuracy and percision for up to 18 analytes...
Sera available in three levels for the control of accuracy and precision for up to 31 analytes...
Human based material available in two levels for the control of accuracy and precision for upto 23 analytes....
Human based assayed sera available in three levels for the control of accuracy and precision for up to 25 analytes...
Medicine Products: